Danaher appoints Daniel Comas and Robert Hershberg to its board of directors

Danaher said it appointed Daniel L. Comas and Robert Hershberg, M.D., Ph.D., to its Board of Directors on October 9, 2026. Hershberg was also appointed to the company's Science and Technology Committee.

Danaher said Alan G. Spoon will not stand for reelection at its 2027 Annual Meeting of Shareholders. Danaher said he will retire from the board at that time. The company said it has expanded the board from 11 to 13 directors to accommodate the appointments. Its Nominating & Governance Committee continues to evaluate board composition as part of its regular governance and refreshment processes.

Steven M. Rales, Chairman of the Danaher Board of Directors, said Comas has deep knowledge of Danaher, the Danaher Business System and the company's approach to strategy and capital allocation. He said Hershberg brings scientific, clinical and biopharmaceutical expertise, and experience advancing innovation that improves patient outcomes.

Comas joined Danaher in 1991 and served as Chief Financial Officer from April 2005 through December 2018. He retired in March 2024 and served as a consultant to the company through September 2026. Hershberg served as President, Chief Executive Officer and Chairman of HilleVax, Inc. from March 2020 through September 2025.